TP53 and intrahepatic cholangiocarcinoma: For example, in the absence of a detailed analysis of the TP53 locus (using CBA, FISH, or chromosomal microarray), both WHO and ICC consider >50% VAF as presumptive evidence multi-hit, though the evidence suggests that VAF estimation is a poor surrogate for the allelic status [2].